Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT6AM2)

Drug Name

Ozanimod Drug Info

Synonyms

1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
Ulcerative colitis	DD71	Phase 3	[3]
Crohn disease	DD70	Phase 2	[3]

Cross-matching ID

PubChem CID: 52938427
CAS Number: CAS 1306760-87-1
TTD Drug ID: DMT6AM2
ACDINA Drug ID: D01311

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sphingosine-1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siponimod	DM2R86O	Multiple sclerosis	8A40	Approved	[4]
Fingolimod	DM5JVAN	Primary progressive multiple sclerosis	8A40.1	Approved	[5]
Ponesimod	DMEAOYJ	Multiple sclerosis	8A40	Approved	[6]
APD-334	DMT0A3Y	Ulcerative colitis	DD71	Phase 3	[3]
MT-1303	DMSE9TH	Crohn disease	DD70	Phase 2	[7]
ONO-4641	DMLUM3Y	Rheumatoid arthritis	FA20	Phase 2	[8]
KRP-203	DMOW9X2	Cutaneous lupus erythematosus	EB5Z	Phase 2	[8]
Sphingosine-1-Phosphate	DMJCQKA	Acne vulgaris	ED80	Phase 1	[9]
ASP-4058	DM1RD0T	Multiple sclerosis	8A40	Phase 1	[10]
GSK-2018682	DMRU4YV	Immune System disease	4A01-4B41	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT02294058) Phase 3 Study of RPC1063 in Relapsing MS. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
8	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
9	Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.
10	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.